Pharmacy benefit administration.
SB 503 restructures how Indiana may administer prescription drug benefits for two major public programs: the state employee health plan and Medicaid. It authorizes the State Personnel Department and the Office of the Secretary of Family and Social Services to seek proposals for a public-private partnership to operate pharmacy benefit manager functions, while setting detailed procurement rules, eligibility standards for bidders, reporting requirements, and oversight mechanisms. The bill also requires that any selected pharmacy benefit partner be independent from insurance companies and pharmacies, have relevant experience and cost-savings history, and operate under a flat-fee administrative model.
The bill further requires full pass-through of rebates to the state employee health plan or Medicaid, monthly disclosure of rebate amounts, quarterly reporting to a newly created pharmacy benefit compliance officer, and potential civil penalties for noncompliance. It creates a pharmacy benefit compliance fund to pay the officer and administer the chapter, and it directs the attorney general to conduct audits after implementation to measure savings, claims processing, health outcomes, and participant satisfaction. The bill also expands the Health Care Cost Oversight Task Force’s study duties to include pharmacy benefit manager issues, prescription drug costs, market competition, and related health care pricing topics.
SB 503 would amend multiple areas of Indiana law governing state employee health benefits, Medicaid administration, insurance oversight, and health care cost review. It creates new chapters authorizing public-private pharmacy benefit manager contracts, establishes a pharmacy benefit compliance officer within the attorney general’s office, and sets up a dedicated compliance fund. It also requires audits, reporting, and enforcement tools tied to prescription drug benefit contracts, while modifying the health care cost oversight task force’s responsibilities to include broader review of drug pricing and market competition. The bill affects the State Personnel Department, FSSA, the attorney general, the budget committee, pharmacy benefit partners, drug manufacturers, and Medicaid/state employee plan participants.
The committee record shows strong support in the Senate Committee on Health and Provider Services, where the bill was reported favorably by an 11-0 vote after amendment. The amended version appears to have been crafted to preserve the bill’s core policy goals while softening some mandatory language and clarifying review and hearing procedures. Overall, the sentiment reflected in the available history is positive and reform-oriented, with an emphasis on transparency, competition, and cost containment in prescription drug administration.
The main policy tensions in SB 503 center on how much control the state should retain over pharmacy benefit management and how aggressively it should regulate contractors. The bill excludes pharmacy benefit partners affiliated with insurers or pharmacies, requires 100% rebate pass-through, and imposes audits and penalties, which suggests concern about conflicts of interest and opaque pricing practices. At the same time, the amended bill replaces several mandatory steps with permissive ones, indicating some sensitivity to administrative flexibility and procurement practicality. No recorded committee opposition appears in the available materials, but the structure of the bill suggests the likely points of debate were contractor independence, rebate treatment, state oversight, and the feasibility of the procurement and audit requirements.